Anifrolumab inhibits cytokine production, plasmacytoid dendritic cell (pDC) activation and the type I (interferon gene signature) IFN gene signature. Anifrolumab.

Slides:

Advertisements

Similar presentations

Side Scatter Forward Scatter Lineage CD1c CD141 CD303 lineage negative

Advertisements

Figure 1. CD11b+CD33+CD14+HLA-DR−/lo myeloid-derived suppressor cell expansion by human immunodeficiency virus.

The beauty of TLR agonists for CTCL

Memory B cells IgM only Marginal zone B cells without plasmablasts

Impaired Toll-like receptor 8–mediated IL-6 and TNF-α production in antigen-presenting cells from patients with X-linked agammaglobulinemia by Klára Sochorová,

by Lianne van de Laar, Aniek van den Bosch, André Boonstra, Rekha S

by Masih Ostad, Margareta Andersson, Astrid Gruber, and Anne Sundblad

by Rui Zhang, Jeffrey D. Lifson, and Claire Chougnet

Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses by Giulia Nizzoli, Jana Krietsch, Anja Weick, Svenja.

Anifrolumab inhibits type I interferon (IFN)-induced IFN-stimulated response element (ISRE) signalling. Anifrolumab inhibits type I interferon (IFN)-induced.

Interleukin (IL)-1β-producing cells in peripheral blood mononuclear cells (PBMCs). Interleukin (IL)-1β-producing cells in peripheral blood mononuclear.

Cytokine and chemokine expression of flucloxacillin-specific T cell clones (TCC) of patient P1. Cytokine and chemokine expression of flucloxacillin-specific.

Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients by Devi.

FIG. S4. IL-8 IL-10 IL-12 IL-6 TNF IFN-γ

Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15 by Maria Wysocka, Bernice M. Benoit, Sarah.

HLA-A*0201+ Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients Caroline Aspord, Marie-Therese Leccia, Dimitri Salameire,

Figure 2 Anti-LINGO-1 (Li81) does not affect cytokine production

Figure 5 Treatment with fingolimod raises the activation threshold of monocytes in MS Peripheral blood mononuclear cells from 8 healthy donors, 7 patients.

Fig. 2. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral blood. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral.

Pathogenic mechanisms involved in psoriasiform skin lesions during anti-TNF-α therapy. Pathogenic mechanisms involved in psoriasiform skin lesions during.

Interferon- Activates Multiple STAT Proteins and Upregulates Proliferation-Associated IL-2R, c-myc, and pim-1 Genes in Human T Cells by Sampsa Matikainen,

Fig. 1 pDCs infiltrate the skin of SSc patients and spontaneously secrete IFN-α and CXCL4. pDCs infiltrate the skin of SSc patients and spontaneously secrete.

Fig. 3 TLR8 signaling induces CXCL4 and IFN-α secretion by SSc PDCs.

Toll-like receptor 9 suppression in plasmacytoid dendritic cells after IgE-dependent activation is mediated by autocrine TNF-α John T. Schroeder, PhD,

Fig. 4 Expression of cleaved caspase 3, PD-L1, and PD-1 in HGGs after reovirus treatment. Expression of cleaved caspase 3, PD-L1, and PD-1 in HGGs after.

Figure 4 Abundance of cytokines which showed significant difference in expression in the plasma and the cultured PBMC of patients with RRMS Abundance of.

T-cell responses against tuberculin and sensitin in children with tuberculosis and non- tuberculosis mycobacterial lymphadenopathy K. Magdorf, S.D. Schuck,

HLA-A*0201+ Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients Caroline Aspord, Marie-Therese Leccia, Dimitri Salameire,

Human MSC Suppression Correlates With Cytokine Induction of Indoleamine 2,3- Dioxygenase and Bystander M2 Macrophage Differentiation Moïra François, Raphaëlle.

Volume 19, Issue 11, Pages (November 2011)

Nat. Rev. Nephrol. doi: /nrneph

The Human Skin–Associated Autoantigen α-NAC Activates Monocytes and Dendritic Cells via TLR-2 and Primes an IL-12-Dependent Th1 Response Susanne Hradetzky,

Flow cytometry analysis of TNF-β- and IL-10-producing CD33+ cells.

The landscape of cytokine-producing CD4 T cell populations in the peripheral blood (PB) and in the joints. Venn diagrams show the frequency of overlapping.

Volume 23, Issue 5, Pages (November 2005)

TLR9 deficiency promotes aberrant T cell and myeloid dendritic cell (DC) phenotype in imiquimod-induced autoimmunity. TLR9 deficiency promotes aberrant.

Human PBMC-derived MERS-CoV–specific T cells are multifunctional.

Deficiency of TLR9 promotes more severe renal inflammation in imiquimod-induced autoimmunity. Deficiency of TLR9 promotes more severe renal inflammation.

IL-4 and IL-13 Alter Plasmacytoid Dendritic Cell Responsiveness to CpG DNA and Herpes Simplex Virus-1 Jurjen Tel, Ruurd Torensma, Carl G. Figdor, I.

Figure 3 Cytokine gene expression in PBMC stimulated with PPD or MBP in vitroCytokine messenger RNA transcripts were isolated from peripheral blood mononuclear.

Figure 2 CD4+ T-cell subsets fluorescence-activated cell sorting analysis in peripheral blood mononuclear cells of patients with multiple sclerosis treated.

Figure 1 CD52 expression on innate myeloid and lymphoid cell subsets

Immunohistochemistry (IHC) staining of interferon (IFN)-λ in renal tissue The figure demonstrates a repeated renal biopsy obtained from a patient after.

Figure 2 Natalizumab increases expression of proinflammatory genes and cytokines by CD49d+ memory CD4 cells Natalizumab increases expression of proinflammatory.

No difference in T-cell response between SLE patients and healthy controls upon superantigen stimulation. No difference in T-cell response between SLE.

Receiver operating curve of soluble C3, C4, antibodies to double-stranded DNA (anti-dsDNA) compared with complement C4d levels on erythrocytes (EC4d) and.

PD-1 blockade enhances T-cell function.

IFNα Induces MDSC Maturation and Loss of Suppressive Function

Figure 2 Fingolimod impairs induction of activation markers on human monocytes Peripheral blood mononuclear cells from healthy donors were briefly exposed.

Figure 1. MBP-specific IFN-γ+ but not IL-17+ frequencies are significantly different between patients with MS and HCs MBP-specific IFN-γ+ but not IL-17+

Anifrolumab does not elicit antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) activity. Anifrolumab does.

Figure 2 Effect of DMF therapy on the T helper cell repertoire and cytokine production Effect of DMF therapy on the T helper cell repertoire and cytokine.

Correlations between two measures of type I interferon activity and serum galectin-3-binding protein in the SLE-IFN-α (n=26) and HC-IFN-α (n=10) cohorts.

Serum proteins dysregulated at baseline in patients enrolled in the MUSE study subsetted by IFNGS test status, Cutaneous Lupus Erythematosus Disease Area.

The role of IFN in viral infection over time

Representative example of gating on T-cell subpopulations.

Human IL-10 neutralization results in inhibited expression of intragraft Treg function genes and production of suppressive cytokine IL-10. Human IL-10.

Immune cell populations associated with type I IFNGS test status and disease activity. Immune cell populations associated with type I IFNGS test status.

Cytokine synthesis from mononuclear cells.

Fig. 7 BMS reduces the elevated expression of type I IFN–regulated genes both ex vivo in blood from patients with lupus and in a phase 1 study of.

pDCs from the melanoma environment responded to TLR-L stimulation.

The role of IFN in viral infection over time

PD-1 inhibition stimulates the proliferation and cytokine secretion of exhausted/senescent CD8+ T cells in vitro. PD-1 inhibition stimulates the proliferation.

IFN-γ-producing T-cells in SLE patients and healthy controls upon EBV antigen stimulation. IFN-γ-producing T-cells in SLE patients and healthy controls.

Activated T-cells in SLE patients and healthy controls upon EBV antigen stimulation. Activated T-cells in SLE patients and healthy controls upon EBV antigen.

Distributions of CD4, Th1, and Th2 in adults (n = 16; A) and children (n = 50; B). Distributions of CD4, Th1, and Th2 in adults (n = 16; A) and children.

Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8 by Marie Dominique Ah Kioon, Claudio Tripodo, David Fernandez, Kyriakos.

Fig. 2. Effect of activated vitamin D on immune cells

Mean serum concentration time profiles of anifrolumab following subcutaneous and intravenous administration of anifrolumab.a aData below the limits of.

(A–E) demonstrate a kidney biopsy from a patient with lupus nephritis (LN) class V. Representative micrographs: (A), an inflammatory infiltrate with T.

Presentation transcript:

Anifrolumab inhibits cytokine production, plasmacytoid dendritic cell (pDC) activation and the type I (interferon gene signature) IFN gene signature. Anifrolumab inhibits cytokine production, plasmacytoid dendritic cell (pDC) activation and the type I (interferon gene signature) IFN gene signature. IFN-α production by CpG-A-stimulated and DNA/IgG–immune complexes (DNA-IC)-stimulated (A) peripheral blood mononuclear cells (PBMCs) and (B) pDCs with and without preincubation with anifrolumab or isotype control antibody. Dose–response curve of antibody inhibition of IFN-α from a representative donor stimulated with (A and B, left panel) CpG-A or (A and B, centre panel) DNA-IC and (A and B, right panel) quantification of IFN inhibition in multiple donors at 10 µg/mL (67.7 nM) anifrolumab or isotype control antibody. (C, left panel) Induction of the 21-gene IFN gene signature in CpG-A-stimulated PBMCs from three donors. (C, right panel) Inhibition of the 21-gene IFN gene signature in CpG-A-stimulated PBMCs from seven donors with and without preincubation with anifrolumab or isotype control antibody. (D) CD80 activation and CD83 maturation surface marker expression in CpG-A-stimulated pDCs with and without preincubation with 10 µg/mL (67.7 nM) anifrolumab or isotype control antibody. (E) TNF-α, interleukin (IL)-6 and IL-8 secretion from CpG-A-stimulated pDCs with and without preincubation with 10 µg/mL (67.7 nM) anifrolumab or isotype control antibody. One representative experiment of six replicate experiments in all panels. Values are means and SDs. Jeffrey M Riggs et al. Lupus Sci Med 2018;5:e000261 ©2018 by Lupus Foundation of America